New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2014
06:06 EDTAZNAstraZeneca sees annual revenue over $45B by 2023
AstraZeneca said it is "is providing new, long-term, financial targets which highlight the significant potential for shareholder value creation. From 2017 to 2023 AstraZeneca is targeting strong and consistent revenue growth leading to annual revenues of greater than $45 billion by 2023. Operating leverage is expected to result in core earnings growth in excess of revenue growth during this period." The company said, "Under the new management team, AstraZeneca is executing its strategy successfully and is re-positioned for a return to growth; Significant transformation of the pipeline has already been delivered since 2012; Scientific discoveries have been accelerated to extend the late stage pipeline, including access to multiple technologies which place AstraZeneca at the heart of immuno-oncology development; and Five key growth platforms are sustaining near-term growth and AstraZeneca remains confident that 2017 revenues should be broadly in line with 2013."
News For AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
09:02 EDTAZNAstraZeneca mulls linking bonuses to Pfizer defense pledges, Sunday Times says
Subscribe for More Information
February 27, 2015
06:24 EDTAZNAstraZeneca turning antibiotic R&D into separate subsidiary, Reuters reports
Subscribe for More Information
February 23, 2015
12:53 EDTAZNAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
07:55 EDTAZNJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
February 20, 2015
07:23 EDTAZNAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTAZNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use